Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Revenue: 2009-2025

Historic Revenue for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $205.7 million.

  • Myriad Genetics' Revenue fell 3.56% to $205.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $825.3 million, marking a year-over-year increase of 0.21%. This contributed to the annual value of $837.6 million for FY2024, which is 11.21% up from last year.
  • Latest data reveals that Myriad Genetics reported Revenue of $205.7 million as of Q3 2025, which was down 3.47% from $213.1 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Revenue high stood at $213.3 million for Q3 2024, and its period low was $156.4 million during Q3 2022.
  • Moreover, its 3-year median value for Revenue was $202.2 million (2024), whereas its average is $200.5 million.
  • Data for Myriad Genetics' Revenue shows a peak YoY increase of 103.22% (in 2021) and a maximum YoY decrease of 46.36% (in 2021) over the last 5 years.
  • Myriad Genetics' Revenue (Quarterly) stood at $160.8 million in 2021, then increased by 10.57% to $177.8 million in 2022, then increased by 10.57% to $196.6 million in 2023, then increased by 7.12% to $210.6 million in 2024, then declined by 3.56% to $205.7 million in 2025.
  • Its last three reported values are $205.7 million in Q3 2025, $213.1 million for Q2 2025, and $195.9 million during Q1 2025.